PCN25 TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE PRACTICE- A COST OF ILLNESS AND MODEL VALIDATION STUDY
Nov 1, 2006, 00:00
10.1016/S1098-3015(10)63455-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)63455-9/fulltext
Title :
PCN25 TREATMENT OF ACTINIC KERATOSIS (AK) AND BASAL CELL CARCINOMA (BCC) WITH METVIX® (MAL-PDT) IN REAL LIFE PRACTICE- A COST OF ILLNESS AND MODEL VALIDATION STUDY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63455-9&doi=10.1016/S1098-3015(10)63455-9
First page :
Section Title :
Open access? :
No
Section Order :
306